Cazzola M, Guidetti E, Sepe J, Assogna G, Lucchetti G, Santangelo G, D'Amato G
Division of Occupational Pulmonary Disease and Respiratory Allergy, A. Cardarelli Hospital, Naples, Italy.
Chest. 1990 Apr;97(4):901-5. doi: 10.1378/chest.97.4.901.
In a double-blind, crossover study, nebulized ketanserin, a 5-HT2 receptor antagonist, and a placebo were given to eight patients with moderate to severe nonasthmatic COPD. Intravenous ketanserin had rapid onset of action and induced a longer lasting bronchial response than inhaled ketanserin. These results confirm that ketanserin acts as a mild bronchodilator in patients with COPD and demonstrate that the inhaled route has no advantage over the intravenous route in terms of effectiveness. Thus, 5-HT may play a role in bronchomotor tone, at least in patients with chronic airway obstruction.
在一项双盲交叉研究中，对8例中度至重度非哮喘性慢性阻塞性肺疾病（COPD）患者给予雾化酮色林（一种5-羟色胺2受体拮抗剂）和安慰剂。静脉注射酮色林起效迅速，且比吸入酮色林诱导的支气管反应持续时间更长。这些结果证实酮色林在COPD患者中起轻度支气管扩张剂的作用，并表明在有效性方面，吸入途径相对于静脉途径并无优势。因此，5-羟色胺可能在支气管运动张力中起作用，至少在慢性气道阻塞患者中如此。
